Status:
COMPLETED
A Study of LY3437943 in Participants With Type 2 Diabetes
Lead Sponsor:
Eli Lilly and Company
Conditions:
Type 2 Diabetes
Eligibility:
All Genders
18-75 years
Phase:
PHASE2
Brief Summary
The main purpose of this study is to evaluate the efficacy and safety of LY3437943 in participants with type 2 diabetes (T2D) who failed to achieve adequate glycemic control on diet and exercise alone...
Eligibility Criteria
Inclusion
- Have Type 2 Diabetes (T2D)
- Have an HbA1c value at screening of ≥7.0% and ≤10.5% and treated with diet and exercise alone or with a stable dose of metformin (either immediate release or extended release, 1000 milligram (mg)/day and not more than the locally approved dose) for at least 3 months prior to screening.
Exclusion
- Have type 1 diabetes mellitus (T1DM)
- Have ketoacidosis
- Have retinopathy, maculopathy
- Have history of pancreatitis
- Have obesity induced by other endocrine disorders
- Have uncontrolled hypertension
- Have acute or chronic hepatitis
- Have chronic kidney disease
- Have an autoimmune abnormality for example, lupus or rheumatoid arthritis
- Have an active or untreated malignancy
Key Trial Info
Start Date :
May 13 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 27 2022
Estimated Enrollment :
281 Patients enrolled
Trial Details
Trial ID
NCT04867785
Start Date
May 13 2021
End Date
October 27 2022
Last Update
July 3 2023
Active Locations (43)
Enter a location and click search to find clinical trials sorted by distance.
1
Syed Research Consultants Llc
Sheffield, Alabama, United States, 35660
2
San Fernando Valley Health Institute
Canoga Park, California, United States, 91304
3
Valley Endocrine, Fresno
Fresno, California, United States, 93720
4
National Research Institute - Huntington Park
Huntington Park, California, United States, 90255